Zacks Research Has Bearish Estimate for ENSC Q3 Earnings

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Equities research analysts at Zacks Research decreased their Q3 2026 earnings estimates for Ensysce Biosciences in a research report issued on Thursday, August 6th. Zacks Research analyst B. Sorensen now anticipates that the company will post earnings of $0.04 per share for the quarter, down from their prior forecast of $0.09. The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($1.53) per share. Zacks Research also issued estimates for Ensysce Biosciences’ Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.27) EPS and FY2027 earnings at ($0.05) EPS.

Ensysce Biosciences (NASDAQ:ENSC) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.21. Ensysce Biosciences had a negative net margin of 250.39% and a negative return on equity of 766.45%. The business had revenue of $0.96 million during the quarter, compared to the consensus estimate of $1.00 million.

A number of other research firms have also issued reports on ENSC. Wall Street Zen upgraded Ensysce Biosciences to a “hold” rating in a report on Saturday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Ensysce Biosciences currently has a consensus rating of “Sell”.

Ensysce Biosciences Stock Performance

NASDAQ ENSC opened at $0.43 on Tuesday. Ensysce Biosciences has a twelve month low of $0.23 and a twelve month high of $2.75. The stock has a market cap of $6.62 million, a price-to-earnings ratio of -0.13 and a beta of 0.84. The firm’s 50 day moving average price is $0.29 and its two-hundred day moving average price is $0.42.

Hedge Funds Weigh In On Ensysce Biosciences

Hedge funds have recently modified their holdings of the stock. Citadel Advisors LLC purchased a new stake in shares of Ensysce Biosciences during the third quarter worth $34,000. Virtu Financial LLC acquired a new stake in Ensysce Biosciences during the third quarter valued at $34,000. DRW Securities LLC boosted its position in Ensysce Biosciences by 42.4% during the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after purchasing an additional 29,336 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its stake in Ensysce Biosciences by 100.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after purchasing an additional 75,000 shares in the last quarter. 5.63% of the stock is owned by institutional investors and hedge funds.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.